Date of Award

Winter 12-12-2024

Degree Type

Dissertation/Thesis

Degree Name

Master of Science in Chemical Sciences (MSCB)

Department

Chemistry and Biochemistry

Committee Chair/First Advisor

Dr. Thomas C. Leeper

Second Advisor

Dr. Animesh Aditya

Third Advisor

Dr. Glen Meades

Abstract

Multi-drug resistance poses a serious threat to future generations and historical antibiotic pipelines; consequently, the medical and economic burdens associated with treating multidrug-resistant bacteria are substantiated. In this context, P. aeruginosa (PA) emerges as one of the most significant healthcare challenges, being a leading cause of resistance-associated mortality worldwide. Despite modern efforts to combat these poor outcomes, drug-resistant cases continue to rise, and the need for novel antibiotic treatment is apparent. To this end, we investigated relevant resistance mechanisms and past antibiotic targets within PA, and in doing so, we identified relationships between peptidoglycan biology and a periplasmic protein, Inhibitor of Vertebrate Lysozyme (Ivyp1). Following this connection and previous reports, we formulated a drug discovery campaign to satisfy the need for novel antibiotics in PA. Our hypothesis poses that drug-based inhibition of Ivyp1 will perturb peptidoglycan biology in P. aeruginosa, rendering PA susceptible to combinatorial antibiotic treatments. Here, we report the rational design and synthesis of three targeted covalent inhibitor-like molecules (compounds 3a-3c) against Ivyp1. Specifically, our scaffold makes use of a non-covalent driving group, aliphatic linkers, and a rhenium(I)-based warhead to direct covalent modification at a biologically relevant site. NMR-guided characterizations of synthetic intermediates (compounds 1a-1c) with Ivyp1 support a potential mechanism of drug-based inhibition; however, solubility issues prevented similar protein-based investigations with compounds (3a-3c), ultimately obstructing our progress. In all, this work builds the foundation for a drug discovery campaign against P. aeruginosa—in which a novel, drug-based modulator of peptidoglycan biology is discovered—while also highlighting frequent obstacles in drug and antibiotic discovery. Future experiments will expand on our synthetic results and pursue structure-activity relationships.

Share

COinS